Topic Listing for Spectrum Pharmaceuticals

Accounting Share-based Compensation Accounting Share-based Employee Compensation
Accounting Stock-based Employee Compensation Achieved Such Potential Contingent Issuances Aggregated Approximately Shares
Acquire Additional Businesses Not Successfully Integrate Operations Acquired In-process Research Development
Actual Future Payments Allowances Discounts Returns Rebates Chargebacks Additional Information
Adjudication Licensed Patents Adjustments Changes Capitalization Dissolution Liquidation Merger Asset Sale
Administration Plan Adverse Event
Adverse Outcome Arbitration Proceedings Gpc Biotech Hurt Financial After Approval Lfa Market Before End 2007
Agreement Plan Merger Amendment Licence Agreement
Amendment Termination Amendment Termination Plan
Anticipated Events Milestones Applicable Law
Approve Adoption Spectrum Pharmaceuticals Inc 2009 Employee Stock Approve Adoption Spectrum Pharmaceuticals Inc 2009 Incentive Award
Arbitration Gpc Biotech Assignability
Assignment Attend Annual Meeting
Attestation Report Registered Public Accounting Firm Audit Committee
Audit Fees Audit Related Fees
Authorized Stock Base Salary Bonuses
Basic Diluted Net Loss Per Share Basis Presentation
Beneficial Ownership Reporting Compliance Benign Prostatic Hyperplasia
Benign Prostatic Hypertrophy Board Committees
Board Independence Board Meeting Attendance
Business Business Alliances
Business Not Generate Cash Needed Finance Ongoing Operations Business Not Generate Sufficient Cash Finance Ongoing Operations
Business Outlook Business Strategy
Calcium Levofolinate L-calcium Folinate Cancer
Cash Cash Compensation
Cash Equivalents Marketable Securities Certain Features Awards 2009 Plan
Certain Relationships Related Transactions Certain Risks Concentrations
Certificate Amendment Incorporation Amended Spectrum Pharmaceuticals Inc Delaware Certification Chief Executive Officer
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act Certification Vice President Finance
Certification Vice President Finance Pursuant 302 Sarbanes-oxley Act Change Control
Change Vote After Return Proxy Card Changes Lateral Control Over Financial Reporting
Charter Documents Directors Officers Chemicals Pharmaceuticals Limited
Chief Executive Officer Compensation Clinical Trials Fail Demonstrate Safety Efficacy Drug Products
Clinical Trials Fail Demonstrate Safety Efficacy Proprietary Drug Code Business Conduct Ethics
Collaborations Outside Scientists Subject Change Limit Access Expertise Common Stock
Common Stock Issuances Cash Common Stock Reserved Future Issuance
Communications Board Communications Board Directors
Comparison Cumulative Total Returns Compensation
Compensation Benefits Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Philosophy
Compensation Philosophy Objectives Competition
Competition Generic Products Competition Patients Conducting Clinical Trials Prevent Delay Product
Competition Proprietary Products Completion Acquisition Disposition Assets
Comprehensive Income Comprehensive Loss
Concentrations Credit Risk Concentrations Credit Risk Supplier Customer
Conference Call Conference Call Today 2006 1200 Eastern Time 900
Confidentiality Conflicts Partners Delay Prevent Development Commercialization Drug Products
Conflicts Partners Delay Prevent Development Commercialization Product Candidates Consent Independent Registered Public Accounting Firm
Consolidated Financial Statements Consolidation Drug Wholesalers Other Wholesaler Actions Increase Competitive
Contractual Commercial Obligations Controls Procedures
Corporate Background Available Information Corporate Compliance Program Not Ensure Applicable Fraud Abuse
Corporation Law State Delaware Critical Accounting Policies Estimates
Customers Definitions
Delaware Corporation Delivery Payment Title Product
Delivery Timing Dependent Parties Marketing Proposed Proprietary Products Not Able
Dependent Party Market Sell Distribute Generic Product Sumatriptan Description 2009 Plan
Development Drug Candidate Ozarelix Adversely Affected Efforts Zentaris Development Drug Candidate Satraplatin Depends Efforts Party Therefore
Development Drug Product Apaziquone Adversely Affected Efforts Allergan Development Drug Product Ozarelix Adversely Affected Efforts Aeterna
Development Drug Product Satraplatin Depends Efforts Party Therefore Director Compensation
Disclosure Controls Procedures Discovery Previously Unknown Problems Drug Products Approved Market
Dispute Resolution Dividends
Documents Incorporated Reference Drug Candidate Lfa Not Effective Safer Cost Efficient
Drug Product Candidates Drug Product Fusilev Not Cost Efficient Competing Drugs
Drug Product Levoleucovorin Not Cost Efficient Competing Drugs Drug Products Not Effective Safer Cost-efficient Competing Otherwise
Effective Date Effective Date Agreement Insert
Efforts Acquire In-license Develop Additional Drug Products Fail Efforts Acquire In-license Develop Additional Proprietary Drug Candidates
Eligibility Eligibility Participation
Eligible Employees Employees
Employment Agreement Employment Agreements
Employment Severance Agreements End Option Values
Entitled Vote Annual Meeting Entry Material Definitive Agreement
Eoquin Epro Bank Account
Equity Compensation Plan Information Equity Incentive Awards
Estimates Even After Receive Regulatory Approval Market Drug Products
Events Milestones Eventual Fda Approval Subsequent Marketing Sale Drug Candidate
Evolve Primarily Involved Development Also Commercialization Encounter Difficulties Exact Name Registrant Specified Charter
Executive Compensation Summary Table Executive Employment Agreements Termination Change-in-control Arrangements
Executive Officer Compensation Policy Executive Officers
Exhibits Face Difficulties Achieving Broader Market Acceptance Zevalin Not
Facility Equipment Leases Failure Comply Advertising Regulations Enforced Fda Federal Trade
Failure Comply Fda Related Regulations Applicable Business Subject Failure Comply Governmental Regulations Delay Prevent Approval Drug
Failure Comply Governmental Regulations Delay Prevent Approval Product Failure Obtain Regulatory Approval Outside United States Prevent
Fair Value Financial Instruments Fda Enforcement
Federal Income Tax Consequences Financial Statements Exhibits
Financial Statements Pro Forma Information Exhibits Force Majeure
Foreign Regulation Form 10-k
Form Conversion Notice Form Pharmacovigilance Agreement
Form Quality Agreement Former Name Address Changed Since Last Report
Forward-looking Statement Forward-looking Statements
General General Information Drug Approval Process
General Information Drug Approval Process Post-marketing Requirements Glaxo Group Limited
Glaxo Wellcome Manufacturing Pte Limited Governmental Regulation
Grant License Grant Purchase Rights
Grants Plan Based Awards 2006 Gsk Supplied Product Initial Par Estimate
Gsk Supplied Product Specifications Gsk Supplied Products
Guidelines Recommendations Published Various Organizations Reduce Products Hazardous Materials Research Development Efforts Imposes Certain Compliance
Headings Interpretation Healthcare Reform
Held Friday 2007 Held Friday 2008
Held Friday 2009 Http Wwwspectrumpharmcom
Impact Accounting Tax Treatments Compensation Important Notice Regarding Availability Proxy Materials Stockholder Meeting
Important-please Sign Date Other Side Return Promptly Inability Retain Attract Key Personnel Significantly Hinder Growth
Income Taxes Indemnification Insurance Dispute Resolution
Indemnities Independent Contractors
Index Index Financial Statements
Industry Segment Geographic Information Initial Quantity
Inspection Manufacturing Compliance Acceptance Product Instructions Withhold Authority Vote Nominee Print Nominees Name
Insurance Intellectual Property
Intellectual Property Assets Owned Subsidiary Rit Subject Security Intellectual Property Confidential Information
Intellectual Property Litigation Increasingly Common Expensive Result Restrictions Intellectual Property Rights
Intellectual Property Rights Complex Uncertain Therefore Subject Infringement Intense Competition Large Number Generic Companies Make Marketing
Internal Control Over Financial Reporting Inventory
Irvine 92618 Irvine California 2007 Spectrum Pharmaceuticals Inc Nasdaq Sppi
Irvine California 92618 Kelly
Key Elements 2005 Executive Compensation Key Elements Executive Compensation
Key Upcoming Milestones Legal Proceedings
Legislative Regulatory Reform Healthcare System Pharmaceutical Industry Hurt Legislative Regulatory Reform Healthcare System Pharmaceutical Industry Related
Lfa Levofolinic Acid License Agreement
Licensing Agreements Like Other Early-stage Biotech Companies History Operating Losses
Liquidity Capital Resources Litigation
Losses Continue Increase Expand Development Efforts Never Result Managements Annual Report Internal Control Over Financial Reporting
Manner Conversion Stock Manufacturing
Manufacturing Supply Agreement Market Price Trading Volume Common Stock Fluctuate Significantly
Market Price Volume Common Stock Fluctuate Significantly Result Market Products Manner Violates Health Care Anti-kickback Other
Market Products Manner Violates Health Care Fraud Abuse Market Securities
Marketing Sale Drug Product Levoleucovorin Adversely Affected Sales Marketing Sale Fusilev Zevalin Adversely Affected Sales Efforts
Merger Miscellaneous
Miscellaneous Matters Miscellaneous Provisions
Name Age Need Party Assist Marketing Levoleucovorin Required Not Able
Neotherapeutics Inc Neotherapeutics Inc Colorado Corporation
Net Cash Provided Financing Activities Net Cash Provided Used Financing Activities
Net Cash Provided Used Investing Activities Net Cash Used Investing Activities
Net Cash Used Operating Activities New Accounting Pronouncements
New Plan Benefits Nominating Corporate Governance Committee
Not Able Obtain Co-promotion Rights United States Regard Not Anticipate Declaring Cash Dividends Common Stock
Not Successful Establishing Additional Active Pharmaceutical Ingredient Finished Not Successful Obtaining Regulatory Approval Market Sell Drug
Not Successful Obtaining Regulatory Approval Market Sell Proprietary Notice Annual Meeting Stockholders Held Thursday 2006
Notices Now Therefore
Offering Offering Periods
Operational Flexibility Regulatory Proficiency Extensive Research Development Capabilities Option Grants 2004
Options Orphan Drug Designation
Other Other Equity Transactions
Other Events Other Fees
Other Information Not Previously Reported Form 8-k Other Matters
Overview Overview Cancer
Overview Major Indications Targeting Ozarelix
Ozarelix Patients Benign Prostatic Hypertrophy Ozarelix Spi-153 D-63153 Development Alliance Aeterna Zentaris
Pacific Time Packaging Guidelines
Page Par Pharmaceutical Alliance
Par Pharmaceutical Inc Paragraph Certification
Part Participation
Party Reimbursement Pricing Controls Patent Process
Patents Licenses Patents Proprietary Rights
Patents Proprietary Rights Andas Payments
Payments Termination Employment Change-in-control Payroll Deductions
Pediatric Exclusivity Pipeline Review
Placement Committee Plan Administration
Plan Matching Contribution Plan Shares
Policy Audit Committee Pre-approval Permissible Non-audit Services Independent Policy Respect 162
Policy Review Approval Ratification Transactions Related Persons Power Attorney
Preamble Preferred Stock
Pregnancy Price Other Competitive Pressures Make Marketing Sale Generic
Prices Principal Accountant Fees Services
Principal Accounting Fees Services Principles Consolidation
Principles Consolidation Basis Presentation Product Acquisition Committee
Product Manufacture Product Portfolio
Products Development Products Strategic Alliances
Property Equipment Proposal 2-approval Amendment Certificate Incorporation Increase Authorized Common
Proposal Election Directors Proprietary Drug Candidate Lfa Not Effective Safer Cost
Proprietary Drug Candidates Not Effective Safer Cost-efficient Competing Prostate Cancer
Provisions Charter Bylaws Stockholder Rights Plan Make Difficult Proxy Solicitation Costs
Proxy Statement Publicly-filed Sec Reports Reviewed Time Significant Changes Required
Purchase Price Allocation Purchase Stock
Purpose Plan Purposes Plan
Pursuant 302 Sarbanes-oxley Act 2002 Quantitative Qualitative Disclosures Market Risk
Questions Answers 2005 Annual Meeting Voting Questions Answers 2007 Annual Meeting Voting
Questions Answers 2008 Annual Meeting Voting Questions Answers 2009 Annual Meeting Voting
Rapid Bio-technological Advancement Render Drug Candidates Obsolete Before Rapid Bio-technological Advancement Render Drug Products Obsolete Before
Raw Materials Packaging Recent Developments
Recent Highlights Recitals
Reclassification Accounts Recommendation Board Directors
Regarding Forward-looking Statements Registrants Telephone Number Including Area Code 949 788-6700
Regulatory Exclusivities Rely Contract Research Organizations Other Parties Conduct Clinical
Report Audit Committee Report Compensation Committee
Report Independent Registered Public Accounting Firm Representations Warranties Indemnification
Research Development Restricted Stock
Restricted Stock Units Results Operations
Results Operations 2005 Compared 2004 Results Operations 2006 Compared 2005
Results Operations 2007 Compared 2006 Results Operations 2008 Compared 2007
Results Operations Financial Conditions Results Operations Nine-month Period 2006 Compared 2005
Results Operations Six-month Period 2006 Compared 2005 Results Operations Three-month Period 2006 Compared 2005
Revenue Recognition Rights Agreement
Rights Purchase Series Junior Participating Preferred Stock Risk Factors
Sales Marketing Distribution Satraplatin
Schedule 14a Scope Agreement
Securities Exchange Service Agreements
Severability Shares Available 2009 Espp
Shares Common Stock Preferred Outstanding What Voting Rights Signature Page Amendment Development Marketing Agreement
Signature Page Follows Signatures
Signatures Appear Following Page Signatures Follow Next Page
Size Market Potential Products Uncertain Small Relative Principal Competitors Limited Financial Resources Limit
Specification Sumatriptan Succinate Injection Spectrum Deliverables
Spectrum Pharmaceuticals Spectrum Pharmaceuticals Announces 2006 Financial Results Pipeline Update
Spectrum Pharmaceuticals Announces Completion Nda Filing Satraplatin Hormone Spectrum Pharmaceuticals Completes Acquisition Oncology Drug Assets Targent
Spectrum Pharmaceuticals Inc Spectrum Pharmaceuticals Inc 2009 Employee Stock Purchase Plan
Spectrums Highlights Statement Regarding Financial Information
Stipulation Dismissal Stipulations Order Dismissal
Stock Stock Appreciation Rights
Stock Grants Stock Incentive Plan Amended Restated Effective 2006
Stock Options Stock Transfer Corporation
Stock Vested Table 2006 Stock Vested Table 2007
Stock-based Charges Stockholder Proposals 2006 Annual Meeting
Stockholder Proposals 2007 Annual Meeting Stockholders Sharing Same Last Name Address
Subject Damages Resulting Claims Employees Wrongfully Used Disclosed Subject Product Liability Claims Not Sufficient Insurance Cover
Subject Risks Associated Doing Business Internationally Submission Matters Vote Security Holders
Subsequent Events Subsidiaries Registrant
Substantial Number Shares Common Stock Eligible Future Sale Sumatriptan Injection Paragraph Litigation
Sumatriptan Succinate Injection Paragraph Litigation Summary Condensed Consolidated Balance Sheets
Summary Federal Income Tax Consequences 2009 Plan Supplemental Cash Flow Information
Supply Agreements Supply Distribution Agreement
Supply Drug Products Dependent Production Capabilities Cmos Component Table Contents
Table Exhibits Schedules Appendices Tax Fees
Tax Withholding Technical Information Confidentiality
Term 2009 Plan Term Termination
Termination Third-party Payors Not Adequately Reimburse Providers Product Candidates
Third-party Payors Not Adequately Reimburse Providers Products Approved Time Need License Patents Intellectual Property Proprietary Technologies
Transactions Related Parties Types Awards 2009 Plan
Unable Adequately Protect Technology Enforce Patent Rights Business Unable Effectively Maintain Expand Sales Marketing Capabilities Successfully
Unable Establish Sales Marketing Capabilities Successfully Commercialize Levoleucovorin Unable Expand Approved Usage Fusilev Products Operating Results
Unable Expand Approved Usage Zevalin Maintain Obtain Improved Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds V-payments Reports
Vote Vote Required
Vote Telephone Electronically Warranties Representations
Warrants Activity Wednesday 2007 1100 Eastern 800 Pacific
What Boards Recommendation What Boards Recommendations
What Constitutes Quorum What Purpose Annual Meeting
What Vote Required Approve Proposal What Vote Required Approve Proposals
Whereas Withdrawal
Witness Whereof Witnesseth
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki